Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chantui Zhike Granules is a Traditional Chinese Medicine (TCM) botanical formulation developed by the Henan Academy of Chinese Medicine in collaboration with Jinling Pharmaceutical. It is primarily indicated for the treatment of acute tracheobronchitis, specifically targeting the 'wind-heat invading the lung' syndrome characterized by symptoms such as cough. The formulation likely contains *Periostracum Cicadae* (Chantui) as a key component, which is traditionally valued in TCM for its antitussive, anti-inflammatory, and antipyretic properties. The drug is currently undergoing Phase III clinical trials in China to evaluate its efficacy and safety in patients with acute respiratory infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chantui Zhike Granules.